8-K filed Jul 29, 2026 at 07:02 ET
Bausch + Lomb reported Q2 2026 revenue of $1.394B (+9% YoY), slightly above consensus of $1.37B, and adjusted EPS of $0.15, slightly below the $0.16 consensus. The company raised its full-year 2026 revenue guidance to $5.440B-$5.540B and Adjusted EBITDA guidance to $1.025B-$1.075B, citing broad-based growth across all segments, particularly Surgical (+19%) and Pharmaceuticals (+15%). The GAAP net loss narrowed to $14M from $62M a year ago, and operating cash flow improved to $153M from $35M. The stock is likely to move modestly higher on the raised guidance and strong operational momentum, though the adjusted EPS miss tempers the upside.